Iovance Biotherapeutics, Inc.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 24 February 2026: press release. Guidance figures: 1 raised, 2 new, 5 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Quarterly product revenue about $87 million: Fourth quarter total product revenue rose about 30% on the prior quarter, which the company attributed to increasing Amtagvi demand. Source
• Full-year revenue reached guidance range: Full-year 2025 total product revenue was about $264 million, which the company said achieved its $250 million to $300 million guidance range in the first full year of launch. Source
• Real-world response rates lifting demand: Management said real-world response rates are increasing adoption and strengthening referral trends toward earlier treatment. Source
• Gross margin reached about 50%: Fourth quarter gross margin from cost of sales was about 50%, which the company attributed to execution and cost optimization, up from 43% in the third quarter. Source
• NSCLC fast track designation granted: The FDA granted Fast Track Designation for lifileucel in previously treated metastatic nonsquamous NSCLC, for actionable tumor mutations excluding ALK, ROS1 and EGFR. Source
• NSCLC interim response rate 26%: Interim data showed a 26% ORR and mDOR not reached at 25+ months after one-time monotherapy; the company cited docetaxel at 12.8% ORR. Source
• Sarcoma early response rate 50%: Among the first six evaluable patients with advanced UPS or DDLPS refractory to at least one prior line, the confirmed RECIST v1.1 ORR was 50%. Source
• Runway extended into third quarter 2027: The company expects the cash position to fund operations into the third quarter of 2027, later than the second quarter of 2027 given in the prior release. Source

“After ongoing improvements in our operations and gross margin, we are well positioned for future profitability.”

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance

Guidance

What changed from last quarter

• Guidance raised: Cash runway was extended to the third quarter of 2027 from the second quarter of 2027 stated in the prior release. Source
• Ended: The 2025 revenue guidance range, reaffirmed in the third quarter release, is reported as achieved for the full year. Source
• New: The FDA granted Fast Track Designation for lifileucel in previously treated nonsquamous NSCLC; the prior release did not list this designation. Source
• New: Early sarcoma data and a planned single-arm registrational trial in UPS and DDLPS were added in this release. Source
• New: The prior release described a specialty pharmacy agreement as an initiative underway; this release says a specialty pharmacy channel was introduced. Source
• New: The prior release said a strategy with the EMA was being finalized; this release says Iovance is working with the EMA to resubmit in 2026. Source
• New: A five-year analysis of the C-144-01 trial was added, showing about 31% ORR and about 20% five-year overall survival. Source

Results and growth drivers

• Quarterly product revenue about $87 million: Fourth quarter total product revenue rose about 30% on the prior quarter, which the company attributed to increasing Amtagvi demand. Source
• Full-year revenue reached guidance range: Full-year 2025 total product revenue was about $264 million, which the company said achieved its $250 million to $300 million guidance range in the first full year of launch. Source
• Quarterly net loss narrowed: Fourth quarter net loss was $71.9 million, or $0.18 per share, against $78.6 million, or $0.26, a year earlier. Full-year net loss was $391.0 million. Source
• Operating loss compared with prior year: Loss from operations was $73.5 million in the fourth quarter against $86.6 million a year earlier. Full-year operating loss was $403.4 million against $395.3 million. Source

Amtagvi U.S. commercial growth

• Real-world response rates lifting demand: Management said real-world response rates are increasing adoption and strengthening referral trends toward earlier treatment. Source
• Oral data showed 44% response rate: An oral presentation at the 2026 Tandem Meetings reported an overall objective response rate of about 44%, rising to 52% after two or fewer prior lines of therapy. Source
• Community centers started treating patients: The first community treatment centers began treating patients in late 2025 and are expected to add demand in 2026, while academic centers continue to grow. Source
• Specialty pharmacy channel introduced: A specialty pharmacy channel gives authorized treatment centers another way to purchase Amtagvi, alongside the existing ATC purchasing arrangements. Source

“Iovance is poised to create substantial value for patients and shareholders as we increase revenue while advancing our registrational trial in non-small cell lung cancer and best-in-class TIL pipeline in solid tumors.”

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance

Global Amtagvi expansion

• Canada approval already in place: Amtagvi is approved in Canada, with the approval dated August 2025. Source
• UK and Australia reviews pending: Submissions are under review in the United Kingdom and Australia, with potential approvals in the first half of 2026, and Switzerland in the first half of 2027. Source
• EMA resubmission planned for 2026: Iovance is working with the EMA on resubmitting a marketing authorization application in 2026; the prior release described a strategy still being finalized. Source

Costs, gross margin and operations

• Gross margin reached about 50%: Fourth quarter gross margin from cost of sales was about 50%, which the company attributed to execution and cost optimization, up from 43% in the third quarter. Source
• Manufacturing turnaround under 33 days: Manufacturing turnaround improved to 32 days or less from inbound shipment to return shipment to ATCs. Source
• Further cost gains expected in 2026 and 2027: Management expects internalization of lifileucel manufacturing and R&D optimization to drive further improvements in operating expenses, cost of sales and gross margin. Source
• R&D flat, SG&A down in quarter: Fourth quarter R&D expense was $71.2 million, about flat with the prior year; SG&A fell to $36.4 million from $42.3 million. Source

“Growth was driven by increasing demand for Amtagvi.”

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance

Lifileucel clinical and regulatory progress

• NSCLC fast track designation granted: The FDA granted Fast Track Designation for lifileucel in previously treated metastatic nonsquamous NSCLC, for actionable tumor mutations excluding ALK, ROS1 and EGFR. Source
• NSCLC interim response rate 26%: Interim data showed a 26% ORR and mDOR not reached at 25+ months after one-time monotherapy; the company cited docetaxel at 12.8% ORR. Source
• NSCLC registrational trial milestones: Plans include presenting updated data at a major 2026 medical meeting, completing enrollment in 2026, and supporting a supplemental BLA for accelerated approval. Source
• Sarcoma early response rate 50%: Among the first six evaluable patients with advanced UPS or DDLPS refractory to at least one prior line, the confirmed RECIST v1.1 ORR was 50%. Source
• Sarcoma registrational trial planned: A single-arm registrational trial in previously treated UPS and DDLPS is planned to start in the second quarter of 2026, with FDA engagement on expedited approval. Source

Next-generation pipeline programs

• Frontline melanoma trial enrollment rising: The TILVANCE-301 trial of lifileucel with pembrolizumab in frontline melanoma saw enrollment accelerate across a broader global footprint. Source
• Phase 2 endometrial and melanoma trials: Phase 2 trials IOV-END-201 and IOV-MEL-202 are investigating lifileucel in previously treated patients with endometrial cancer and melanoma. Source
• IOV-4001 PD-1 inactivated TIL trial: A Phase 1/2 trial is investigating IOV-4001, a PD-1 inactivated TIL therapy, in previously treated advanced melanoma and NSCLC. Source
• IOV-3001 IL-2 analog in trial: A Phase 1/2 trial is investigating IOV-3001, a second-generation modified IL-2 analog used in the TIL treatment regimen. Source
• IOV-5001 IND planned for 2026: IOV-5001, an inducible tethered interleukin-12 TIL therapy, is planned to enter a Phase 1/2 basket trial after an IND submission in the first half of 2026. Source

Cash, runway and share count

• Balance sheet cash about $297 million: Cash, cash equivalents and investments were $297.0 million at December 31, 2025, with $6.0 million restricted cash, summing to the about $303 million cited. Source
• Runway extended into third quarter 2027: The company expects the cash position to fund operations into the third quarter of 2027, later than the second quarter of 2027 given in the prior release. Source
• Stock compensation down sharply: Non-cash stock-based compensation within costs and expenses was $11.8 million in the fourth quarter, against $31.0 million a year earlier. Source
• Weighted-average shares increased: Weighted-average shares were 407.0 million in the fourth quarter, against 304.9 million a year earlier, used in the diluted EPS calculation. Source

Coming up, as management said on 24 February 2026

• UK and Australia approvals expected: Potential approvals are expected in the United Kingdom and Australia in the first half of 2026, with Switzerland in the first half of 2027. Source
• EMA resubmission during 2026: Plans to resubmit the EMA marketing authorization application during 2026. Source
• Sarcoma registrational trial start: Single-arm registrational trial in previously treated UPS and DDLPS to begin in the second quarter of 2026. Source
• Lung trial data and enrollment: Updated data to be presented at a major medical meeting in 2026, with enrollment in the lung registrational trial to complete in 2026. Source
• IOV-5001 IND filing planned: IND submission for IOV-5001 is planned in the first half of 2026, ahead of a Phase 1/2 basket trial. Source
• Further treatment center growth in 2026: Further acceleration of U.S. treatment center growth is anticipated in 2026, after expansion of patient access in 2025. Source
• Operating and gross margin gains expected: Management expects further improvements in operating expenses, cost of sales and gross margin in 2026 and 2027 from operational initiatives. Source

Figures management reported

Earlier plans management reported on

• Met: Management says full-year 2025 product revenue achieved the guidance range set for the first full year of launch. Source
• Not stated: The prior release said manufacturing would be centralized at the iCTC in early 2026; this release refers to internalization of all lifileucel manufacturing without a date. Source

Other quarters

• Q3 FY2026 earnings call
• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q3 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.